Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Neovastat pivotal trial for third cancer indication approved in U.S. and Canada

Jan. 2, 2001

Gilead's NX-211 enters phase II for second cancer indication

Dec. 29, 2000

Sumitomo licenses class of DACH platinum compounds to Aronex

Dec. 29, 2000

Genta's anti-androgen compounds inhibit prostate cancer

Dec. 29, 2000

Combination tgDCC-E1A/radiation therapy enters phase II

Dec. 28, 2000

Pharmaccine collaboration between Oxxon Pharmaccines and Ludwig Institute

Dec. 28, 2000

Orphan grants Kirin Brewery marketing and distribution rights to Busulfex for Asia

Dec. 28, 2000

Bioenvision to codevelop clofarabine for leukemia; mode of action examined at UCSD

Dec. 28, 2000

Novel steroid compounds demonstrate anticancer potential

Dec. 27, 2000

SLIL designs conformationally restricted polyamine analogues for cancer therapy

Dec. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...